ECSP099610A - Compuestos activos biológicamente marcados con fluoro-benzoilo 18f como agentes de diagnóstico por imágenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo - Google Patents
Compuestos activos biológicamente marcados con fluoro-benzoilo 18f como agentes de diagnóstico por imágenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoiloInfo
- Publication number
- ECSP099610A ECSP099610A EC2009009610A ECSP099610A ECSP099610A EC SP099610 A ECSP099610 A EC SP099610A EC 2009009610 A EC2009009610 A EC 2009009610A EC SP099610 A ECSP099610 A EC SP099610A EC SP099610 A ECSP099610 A EC SP099610A
- Authority
- EC
- Ecuador
- Prior art keywords
- benzoilo
- precursors
- iloxo
- benzozo
- iloxi
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/086—Bombesin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Nuclear Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de benceno sustituidos marcados radioactivamente para diagnóstico por imágenes. La presente invención provee métodos para preparar estos compuestos, en particular, para preparar nuevos compuestos que sirven como precursores para la marcación con 18F, y el uso de estos compuestos marcados con 18F para diagnóstico por imágenes. Fórmula (A), donde uno de -Y1, -Y2, -Y3, -Y4 e -Y5 es -A-B-D-P, donde -A-B-D es un enlace o un separador, P es un péptido, un peptidomimético, un oligonucleótido o una molécula pequeña. K es LG-O o W, donde LG- se selecciona del grupo que comprende la fórmula (B), en la cual T es H o Cl, Q es CH o N, K está ausente o es C=O, W es un isótpo radioactivo o no radioactivo de flúor, con mayor preferencia, 18F.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07090035A EP1964848A1 (en) | 2007-03-01 | 2007-03-01 | Radiofluorination methods |
EP07090079A EP1985624A3 (en) | 2007-04-23 | 2007-04-23 | Single step method of radiofluorination of biologically active compounds or biomolecules |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP099610A true ECSP099610A (es) | 2009-10-30 |
Family
ID=39522200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2009009610A ECSP099610A (es) | 2007-03-01 | 2009-09-01 | Compuestos activos biológicamente marcados con fluoro-benzoilo 18f como agentes de diagnóstico por imágenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo |
Country Status (22)
Country | Link |
---|---|
US (1) | US20090317326A1 (es) |
EP (1) | EP2146753A2 (es) |
JP (1) | JP2010520229A (es) |
KR (1) | KR20090119966A (es) |
AR (1) | AR062796A1 (es) |
AU (1) | AU2007348145A1 (es) |
BR (1) | BRPI0721424A2 (es) |
CA (1) | CA2679514A1 (es) |
CL (1) | CL2007002672A1 (es) |
CO (1) | CO6220836A2 (es) |
CR (1) | CR11011A (es) |
DO (1) | DOP2009000210A (es) |
EA (1) | EA200901142A1 (es) |
EC (1) | ECSP099610A (es) |
IL (1) | IL200034A0 (es) |
MX (1) | MX2009009291A (es) |
PA (1) | PA8747701A1 (es) |
PE (1) | PE20081355A1 (es) |
SV (1) | SV2009003364A (es) |
TW (1) | TW200836764A (es) |
UY (1) | UY30595A1 (es) |
WO (1) | WO2008104203A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
US8450466B2 (en) | 2008-03-21 | 2013-05-28 | The General Hosptial Corporation | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders |
US20100227794A1 (en) * | 2008-11-26 | 2010-09-09 | I.S.T. Corporation | Smart contrast agent and method for detecting transition metal ions and treating related disorders |
US20100129290A1 (en) * | 2008-11-26 | 2010-05-27 | I.S.T. Corporation | Smart contrast agent and detection method for detecting transition metal ions |
GB201013808D0 (en) * | 2010-08-18 | 2010-09-29 | Ge Healthcare Ltd | Peptide radiotracer compositions |
KR101478140B1 (ko) * | 2011-05-13 | 2014-12-31 | (주)퓨쳐켐 | 18f-표지 pet 방사성의약품의 전구체 및 그 제조방법 |
CA2838198A1 (en) * | 2011-06-09 | 2012-12-13 | Ge Healthcare Limited | Distillation device and method |
WO2013001088A1 (en) | 2011-06-30 | 2013-01-03 | Piramal Imaging Sa | Direct synthesis of 18f-fluoromethoxy compounds for pet imaging and the provision of new precursors for direct radiosynthesis of protected derivatives of o-([18f]fluoromethyl) tyrosine |
EP2540710A1 (en) | 2011-06-30 | 2013-01-02 | Bayer Schering Pharma Aktiengesellschaft | New precursors for direct radiosynthesis of protected derivatives of O-([18F]Fluoromethyl) tyrosine |
GB201314936D0 (en) | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723578A (en) * | 1987-09-24 | 1998-03-03 | The Administrators Of Tulane Educational Fund | Peptide analogs of bombesin |
US5084555A (en) * | 1989-08-21 | 1992-01-28 | The Administrators Of The Tulane Educational Fund | An octapeptide bombesin analog |
US6083915A (en) * | 1991-05-10 | 2000-07-04 | Biomeasure, Inc. | Method for treating liver cancer |
TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
US6639076B1 (en) * | 1998-08-18 | 2003-10-28 | Eli Lilly And Company | Growth hormone secretagogues |
DE60022508T2 (de) * | 1999-06-14 | 2006-06-08 | Eli Lilly And Co., Indianapolis | Inhibitoren von serin proteasen |
WO2002036173A2 (en) * | 2000-11-03 | 2002-05-10 | Bristol-Myers Squibb Pharma Company | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation |
AU2002228725A1 (en) * | 2000-11-30 | 2002-06-11 | Advanced Research And Technology Institute, Inc. | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds |
TWI311133B (en) * | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
WO2004073650A2 (en) * | 2003-02-20 | 2004-09-02 | University Of South Florida | Peptidomimetic inhibitors of stat3 activity and their medical uses |
GB0305704D0 (en) * | 2003-03-13 | 2003-04-16 | Amersham Plc | Radiofluorination methods |
JP2007524630A (ja) * | 2003-06-25 | 2007-08-30 | バンダービルト・ユニバーシティ | Cox−2標的造影剤 |
GB0420344D0 (en) * | 2004-09-14 | 2004-10-13 | Amersham Plc | Diagnostic compounds |
CN101068577A (zh) * | 2004-10-07 | 2007-11-07 | 皇家飞利浦电子股份有限公司 | 施陶丁格连接在用于显像和治疗的显像和治疗目的试剂盒中的应用 |
WO2006083424A2 (en) * | 2004-12-28 | 2006-08-10 | The Trustees Of Columbia University In The City Of New York | Radiolabeled compounds and uses thereof |
AU2005324905B2 (en) * | 2005-01-17 | 2012-01-19 | Universitaetsklinikum Muenster | 5-pyrrolidinylsulfonyl isatin derivatives |
WO2008028688A2 (en) * | 2006-09-08 | 2008-03-13 | Bayer Schering Pharma Aktiengesellschaft | Compounds and methods for 18f labeled agents |
-
2007
- 2007-09-07 EA EA200901142A patent/EA200901142A1/ru unknown
- 2007-09-07 WO PCT/EP2007/007967 patent/WO2008104203A2/en active Application Filing
- 2007-09-07 MX MX2009009291A patent/MX2009009291A/es not_active Application Discontinuation
- 2007-09-07 KR KR1020097018125A patent/KR20090119966A/ko not_active Application Discontinuation
- 2007-09-07 AU AU2007348145A patent/AU2007348145A1/en not_active Abandoned
- 2007-09-07 BR BRPI0721424-3A patent/BRPI0721424A2/pt not_active IP Right Cessation
- 2007-09-07 CA CA002679514A patent/CA2679514A1/en not_active Abandoned
- 2007-09-07 US US11/851,940 patent/US20090317326A1/en not_active Abandoned
- 2007-09-07 EP EP07802293A patent/EP2146753A2/en not_active Withdrawn
- 2007-09-07 JP JP2009551918A patent/JP2010520229A/ja active Pending
- 2007-09-10 TW TW096133847A patent/TW200836764A/zh unknown
- 2007-09-14 PA PA20078747701A patent/PA8747701A1/es unknown
- 2007-09-14 UY UY30595A patent/UY30595A1/es not_active Application Discontinuation
- 2007-09-14 PE PE2007001248A patent/PE20081355A1/es not_active Application Discontinuation
- 2007-09-14 AR ARP070104088A patent/AR062796A1/es unknown
- 2007-09-14 CL CL200702672A patent/CL2007002672A1/es unknown
-
2009
- 2009-07-23 IL IL200034A patent/IL200034A0/en unknown
- 2009-09-01 SV SV2009003364A patent/SV2009003364A/es not_active Application Discontinuation
- 2009-09-01 EC EC2009009610A patent/ECSP099610A/es unknown
- 2009-09-01 CO CO09092675A patent/CO6220836A2/es not_active Application Discontinuation
- 2009-09-01 DO DO2009000210A patent/DOP2009000210A/es unknown
- 2009-09-01 CR CR11011A patent/CR11011A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR062796A1 (es) | 2008-12-03 |
AU2007348145A1 (en) | 2008-09-04 |
CR11011A (es) | 2009-10-19 |
MX2009009291A (es) | 2009-12-14 |
TW200836764A (en) | 2008-09-16 |
IL200034A0 (en) | 2010-04-15 |
CL2007002672A1 (es) | 2008-09-12 |
WO2008104203A3 (en) | 2009-02-05 |
CA2679514A1 (en) | 2008-09-04 |
UY30595A1 (es) | 2008-09-30 |
EA200901142A1 (ru) | 2010-04-30 |
BRPI0721424A2 (pt) | 2014-03-25 |
JP2010520229A (ja) | 2010-06-10 |
SV2009003364A (es) | 2010-01-27 |
CO6220836A2 (es) | 2010-11-19 |
EP2146753A2 (en) | 2010-01-27 |
KR20090119966A (ko) | 2009-11-23 |
US20090317326A1 (en) | 2009-12-24 |
PA8747701A1 (es) | 2009-08-26 |
WO2008104203A2 (en) | 2008-09-04 |
PE20081355A1 (es) | 2008-12-05 |
DOP2009000210A (es) | 2010-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP099610A (es) | Compuestos activos biológicamente marcados con fluoro-benzoilo 18f como agentes de diagnóstico por imágenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo | |
UY32037A (es) | Daa-piridina | |
AR079641A1 (es) | Compuestos para el diagnostico por imagenes de la muerte de las celulas por apotosis | |
CL2016000883A1 (es) | Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma. | |
AR073361A1 (es) | Combinacion farmaceutica que comprende 3-(-3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico. uso | |
CL2009000734A1 (es) | Compuestos derivados de 4-aminociclohexano sustituido; composicion farmaceutica que comprende a dichos compuestos; y su uso como moduladores del receptor de opioides u y el receptor orl-1 en el tratamiento de la ansiedad, estres, depresion, epilepsia y alzheimer. | |
BRPI0510487A (pt) | agentes de contraste para estudo por imagens de perfusão do miocárdio | |
CR10694A (es) | Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y procedimientos de uso | |
GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
CL2013000100A1 (es) | Composicion que comprende un agente de contraste para rayos x yodado y un portador o excipiente farmaceuticamente aceptable, donde la concentracion de yodo es de 10-170 mgl/ml; un metodo de examen con rayos x que comprende el uso de la composicion. | |
CO6351754A2 (es) | Agentes de contraste que comprenden compuestos fenilo yodados | |
NO20091428L (no) | Forbindelser og metoder for 18F-merkede midler | |
SG194761A1 (en) | Radiolabeled amino acids for diagnostic imaging | |
EA201301334A1 (ru) | Меченные радиоактивными изотопами ингибиторы глутаминилциклазы | |
BR112012021579A2 (pt) | traçador de tomografia por emissão de pósitron, composto precursor, método para preparar o composto precursor, cassete, composição radiofarmacêutica, método de formação de imagem por tomografia por emissão de pósitron, e, método para diagnose de uma condição. | |
SV2009003205A (es) | Derivados de silicio para obtencion de imagenes por tomografia de emision de positrones (pet) | |
DOP2009000173A (es) | Marcacion radioactiva por fluoracion de aziridinas | |
CO2020008834A2 (es) | Nuevo método para preparar compuesto para formación de imágenes | |
MX340487B (es) | Compuestos para usarse en la formacion de imagenes, diagnostico y/o tratamiento de enfermedades del sistema nervioso central. | |
ATE521591T1 (de) | 11c-markierte benzyl-lactam-verbindungen und deren verwendung als bildgebungsmittel | |
MX2013010781A (es) | Compuestos para usarse en formacion de imagenes, diagnostico y/o tratamiento de enfermedades del sistema nervioso central. | |
CL2008002267A1 (es) | Uso de compuestos derivados de pirinmetilsulfinilbencimadazol y piperidinilaminobencimidazol como marcadores especificos para enfermedades neurodegenerativas y patologias tau; y como metodo de diagnostico de enfermedad de alzheimer, y formulacion farmaceutica que comprende dichos compuestos marcados radiactivamente o con fluorescencia. | |
AR074084A1 (es) | Inhibidores radiomarcados del transportador de glicina 1 y composicion farmaceutica que los contiene | |
ES2495266B1 (es) | Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer | |
CL2019003727A1 (es) | Compuesto marcado con 18f para el diagnóstico de cáncer de próstata y uso de este. |